Robert Scott and Matt Nelson, Glaxo SmithKline (GSK)

7 February 2017, 12.00 PM - 7 February 2017, 1.00 PM


 Tuesday, 7th February, 2017
12.00 – 13.00 - Room OS6 – Oakfield House

 Matt Nelson, Head of Genetics, Philadelphia, PA
Robert Scott, Senior Investigator, Stevenage
Glaxo SmithKline (GSK)

 The role of genetic evidence in drug discovery and development: past, present and future  


Matt and Robert will describe recent work at GSK to evaluate the role of genetic evidence in identification of safe and effective drug targets. They will also discuss ongoing and planned approaches to bring genetic evidence to support both therapeutic target discovery and validation.


Matt Nelson is the head of Genetics at GSK, working in Philadelphia, PA, leading a group of scientists to bring genetic evidence into both drug discovery and drug development decisions.  Research activities of personal interest include investigating the role of growing body genome-wide association studies to inform drug target selection and validation, improving pharmacogenetics experiment design and developing methods and strategies for drawing inferences from both small- and large-scale genetic association studies. Matt graduated from the University of Michigan in statistics and human genetics.  He has previously worked for Sequenom and Esperion Therapeutics.

Robert Scott is a Senior Investigator at GSK, based in Stevenage. Robert has recently joined GSK from the MRC Epidemiology Unit in Cambridge and works to bring genetic evidence to support drug discovery and development. Particular interests include use of large-scale real-world studies to support target validation as well as the application of Mendelian randomisation to drug development.



Edit this page